Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R38 | P59533 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26407897 | 0.88 | CA12 (0.46) | TAS2R38CA12CA1CA2CA9 | |
| SCHEMBL14273137 | 0.85 | TAS2R38 (0.56) | TAS2R38CA12CA1CA2CA9 | |
| SCHEMBL9666884 | 0.84 | ALDH1A1 (0.43) | TAS2R38CA12CA1CA2CA9 | |
| SCHEMBL9666774 | 0.81 | CA12 (0.52) | TAS2R38CA12CA1CA2CA9 | |
| SCHEMBL14273135 | 0.80 | TAS2R38 (0.50) | TAS2R38CA12CA1CA2CA9 | |
| SCHEMBL20850739 | 0.77 | — | — | |
| SCHEMBL14273136 | 0.74 | TAS2R38 (0.43) | TAS2R38CA12CA1CA2CA9 | |
| SCHEMBL14273118 | 0.74 | TAS2R38 (0.43) | TAS2R38CA12CA1CA2CA9 | |
| SCHEMBL8740349 | 0.74 | TAS2R38 (0.43) | TAS2R38CA12CA1CA2CA9 | |
| SCHEMBL14273140 | 0.73 | TAS2R38 (0.56) | TAS2R38CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018057590-A1 | COPPER DEPOSITION IN WAFER LEVEL PACKAGING OF INTEGRATED CIRCUITS | MACDERMID ENTHONE INC. (US) | 2018-03-29 | — | — | WO | disclosed |
| US-9862722-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2018-01-09 | — | — | US | disclosed |
| US-20150329550-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2015-11-19 | — | — | US | disclosed |
| US-20150329550-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2015-11-19 | — | — | US | disclosed |
| US-9138436-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-09-22 | — | — | US | disclosed |
| US-9138436-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2015-09-22 | — | — | US | disclosed |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329550-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | TAS2R38 4513/4885CA12 4795/4885CA1 4747/4885 |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | TAS2R38 4513/4885CA12 4795/4885CA1 4747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.